

|  |
| --- |
| CDIS - Victorian Infant Hearing Screening Program (VIHSP) risk factor update |
| Victorian Maternal and Child Health (MCH)  Child Development Information System (CDIS)  April 2023 |
| OFFICIAL |

Contents

[Purpose 1](#_Toc132288476)

[Background 1](#_Toc132288477)

[Process 2](#_Toc132288478)

# Purpose

This practice note has been developed to outline the documentation process for the 2 week VIHSP Newborn hearing screen and the 8 month VIHSP Hearing Follow-up in CDIS Assessments and on the [VIHSP Community Audiology Referral form](https://www.rch.org.au/uploadedFiles/Main/Content/vihsp/VIHSP%20Community%20Audiology%20Referral%20form.pdf).

# Background

In 2020, following consultations with paediatricians, neonatologists, and other newborn hearing screening programs nationally, there was an update to one of the risk factors for hearing loss. This new risk factor was a change to the duration of the use of Ototoxic medication from **3 days or more** to **three or more consecutive doses**.

The Green Book documents the new risk factor in the 2-week VIHSP Newborn hearing screen and the 8-month VIHSP Hearing Follow-up as:

* “Ototoxic medication (e.g., vancomycin, gentamicin or other aminoglycoside antibiotics) for three or more consecutive doses”, shown in Image 1 and Image 2.

|  |  |
| --- | --- |
| Image 1: 2-week VIHSP Newborn hearing screen | Image 2: 8-month VIHSP Hearing Follow-up |
| ***Image 1: 2-week VIHSP Newborn hearing screen*** | ***Image 2: 8-month VIHSP Hearing Follow-up*** |

The new risk factor is still in the process of being reflected in the CDIS Assessments and on the [VIHSP Community Audiology Referral form](https://www.rch.org.au/uploadedFiles/Main/Content/vihsp/VIHSP%20Community%20Audiology%20Referral%20form.pdf) located on the RCH web site. As a result, these forms reflect the 2019 risk factor definition, as shown below.

* “Aminoglycoside antibiotics (e.g., gentamicin) administered for 3 days or more”

# Process

**Until the risk factor description is changed in CDIS Assessments and on the** [VIHSP Community Audiology Referral form](https://www.rch.org.au/uploadedFiles/Main/Content/vihsp/VIHSP%20Community%20Audiology%20Referral%20form.pdf)**, please follow the following documentation process:**

1. If the risk factor “*Ototoxic medication (e.g., vancomycin, gentamicin or other aminoglycoside antibiotics) for three or more consecutive doses”* is identified, **do not tick** the description risk factor “Aminoglycoside antibiotics (e.g., gentamicin) administered for 3 days or more’, **instead**
2. Make an appropriate note in ‘Comments’ in CDIS, by typing in/cut and paste the new risk factor “*Ototoxic medication (e.g., vancomycin, gentamicin or other aminoglycoside antibiotics) for three or more consecutive doses”* as per Image 3,

|  |
| --- |
| Image 3: Example of CDIS documentation for 2-week hearing screen & 8-month hearing follow up AssessmentsImage 3: Example of CDIS documentation for 2-week hearing screen & 8-month hearing follow up Assessments |
| ***Image 3: Example of CDIS documentation for 2-week hearing screen & 8-month hearing follow up Assessments*** |
|  |

and

1. Tick ‘Other’ in the VIHSP Audiology Referral form and type in/cut and paste the new risk factor “*Ototoxic medication (e.g., vancomycin, gentamicin or other aminoglycoside antibiotics) for three or more consecutive doses”*, as per Image 4

|  |
| --- |
| Image 4: Example of documentation for the VIHSP Audiology Referral form |
| ***Image 4: Example of documentation for the VIHSP Audiology Referral form*** |

You will be advised when the new risk factor is reflected in the CDIS Assessments and on the [VIHSP Community Audiology Referral form](https://www.rch.org.au/uploadedFiles/Main/Content/vihsp/VIHSP%20Community%20Audiology%20Referral%20form.pdf). If you have any questions regarding these changes please contact mch@health.vic.gov.au.

|  |
| --- |
| To receive this document in another format, phone 1300 650 172, using the National Relay Service 13 36 77 if required, or [email Community Based Health Services, Policy & Improvement Branch](mailto:mch@health.vic.gov.au) <mch@health.vic.gov.au>.  Authorised and published by the Victorian Government, 1 Treasury Place, Melbourne.  © State of Victoria, Australia, Department of Health, April 2023.  Except where otherwise indicated, the images in this document show models and illustrative settings only, and do not necessarily depict actual services, facilities or recipients of services. This document may contain images of deceased Aboriginal and Torres Strait Islander peoples.  In this document, ‘Aboriginal’ refers to both Aboriginal and Torres Strait Islander people. ‘Indigenous’ or ‘Koori/Koorie’ is retained when part of the title of a report, program or quotation.  **ISBN** 978-1-76131-130-7 **(pdf/online/MS word)**  Available at [health.vic – Child Development Information System](https://www2.health.vic.gov.au/primary-and-community-health/maternal-child-health/child-development-information-system) <<https://www2.health.vic.gov.au/primary-and-community-health/maternal-child-health/child-development-information-system>> |